Dose- and time-dependent response of human leukemia (HL-60) cells to arsenic trioxide treatment

International Journal of Environmental Research and Public Health

Volumn 3, Issue 2, 2006, Pages 136-140

  Yedjou, Clement G ^a   Moore, Pamela ^a   Tchounwou, Paul B ^a  

^a Jackson State University   (United States)

Author keywords

Arsenic trioxide; Cytotoxicity; Exposure time; HL 60 cells; mtt assay

Indexed keywords

ANTHRACYCLINE DERIVATIVE; ARSENIC TRIOXIDE; RETINOIC ACID; ANTINEOPLASTIC AGENT; ORGANOARSENIC DERIVATIVE; OXIDE;

CELL STRAIN HL 60; CELL VIABILITY; CONFERENCE PAPER; CONTROLLED STUDY; CYTOTOXICITY; DOSE TIME EFFECT RELATION; HUMAN; HUMAN CELL; LD 50; PROMYELOCYTIC LEUKEMIA; ARTICLE; CELL PROLIFERATION; CELL SURVIVAL; DOSE RESPONSE; DRUG EFFECT; LEUKEMIA;

ANTINEOPLASTIC AGENTS; ARSENICALS; CELL PROLIFERATION; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; HL-60 CELLS; HUMANS; LEUKEMIA; OXIDES;

EID: 34347390748     PISSN: None     EISSN: 16604601     Source Type: Journal    
DOI: 10.3390/ijerph2006030017     Document Type: Conference Paper

References (27)

1. Antman, K, H.: The history of arsenic trioxide in cancer therapy. The Oncologist, 2001, 6(2), 1-2.
2. Waxman, S.; Anderson, K, C.: History of the development of arsenic derivatives in cancer therapy. The Oncologist 2001, 6(2), 3-10.
3. Soignet, S. L.; Maslak, P.; Wang, Z.-G.; Jhanwar, S.; Calleja, E.; Dardashti, L. J.; Corso, D.; DeBlasio, A.; Gabrilove, J.; Scheinberg, D. A.; Pandolfi, P. P.; Warrell, R. P.: Complete Remission after Treatment of Acute Promyelocytic Leukemia with Arsenic Trioxide. N Engl J Med, 1998, 339, 1341-1348.
4. Soignet, S. L.; Frankel, S. R.; Douer, D.; Tallman, M. S.; Kantarjian H.; Calleja, E.; Stone, R. M.; Kalaycio, M.; Scheinberg, D. A.; Steinherz, P.; Sievers, E. L.; Coutré S.; Dahlberg, S.; Ellison, R.; Warrell R. P., Jr.: United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J. Clin. Oncol. 2001, 19, 3852-3860.
5. Warrell, R. P. Jr.: Pathogenesis and management of acute promyelocytic leukemia. Annu Rev Med, 1996, 47:555.
6. Muller, S., Matunis, M. J. and Dejean, A.: Conjugation of the ubiquitin-related modifier SUMO-1 regulates the partitioning of PML within the nucleus. EMBO J. 1998, 17, 61-70.
7. Hei T; Liu S; Waldren C.: Mutagenicity of arsenic in mammalian cells: role of reactive oxygen species. Proc Natl Acad Sci USA., 1998, 95, 8103-8107.
8. IARC, Monographs on the Evaluation of Carcinogenic Risks of Chemicals to Humans. Supplement F.: Overall Evaluation of Carcinogenicity. International Agency for Research on Cancer, World Health Organization, Lyon, France, 1987, pp 29-57.
9. Wu, M. M.; Kuo, T. L.; Hwang, Y. H.; Chen, C. J.: Dose-response relation between arsenic concentration in well water and mortality from cancers and vascular diseases. Am J Epidemiol. 1989, 130, 1123-1132.
10. Abernathy, C. O., Liu, Y. P., Longfellow, D., Aposhian, H. V., Beck, B., Fowler, B., Goyer, R., Menzer, R.: Arsenic: health effects, mechanisms of actions, and research issues. Environ Health Perspect, 1999, 107:593-597.
11. Grad, J. M.; Bahlis, N. J.; Reis, I.; Oshiro, M. M.; Dalton, W. S.; and Boise, L. H.: Ascorbic acid enhances arsenic trioxide-induced cytotoxicity in multiple myeloma cells. Blood, 2001, 98, 805-813.
12. Agency for Toxic Substances and Disease Registry. Arsenic. Available at http://www.atsdr.cdc.gov/tfacts2.html. Last updated 1993.
13. NRCC, Effects or arsenic in the environment. National Research Council of Canada. Natl. Res. Counc. Canada Pub. 1978, pp. 1-349.
14. 2) cells exposed to arsenic trioxide and monosodium acid methanearsonate (MSMA). Int J Mol Sci, 2002, 3, 1117-1132.
15. 2). Cellular and Molecular Biology™. 2003, 49 (7), 1071-1079.
16. Freshney, R. I.: Culture of Animal Cells. A manual of basic techniques. Alan Liss Inc (University Library), 1983.
17. Paul, J.: Cell and Tissue Culture. Churchill Livingstone (CSL). 1975.
18. Mosmann, T.: Rapid colorimetric assay for cellular growth and survival: applications to proliferation and cytotoxicity assays. J Immunol Methods, 1983, 65 (1-2): 55-63.
19. Tchounwou, P. B.; Wilson, B.; Schneider, J.; Ishaque, A.: Cytogenic assessment of arsenic trioxide toxicity in the Mutatox, Ames II and CAT-Tox assays. Metal Ions Biol. Med, 2000, 6, 89-91.
20. Todd, A. C.; Wetmur, J. G.; Moline, J. M.; Godbold J. H.; Levin, S. M.; Landrigan, P. J.: Unraveling the chronic toxicity of lead: an essential priority for environmental health. Environ Health Perspect. 1996, 104, 141-146.
21. Jing, Y.; Dai, J.; Charmers-Redman, R. M.; Tatton, W. G.; Waxman, S.: Arsenic trioxide selectively induces acute promyelocytic leukemia cell apoptosis via a hydrogen peroxide-dependent pathway. Blood, 1999, 94, 102-2111.
22. Jai, P.; Chen, G.; Huang, X.; Cai, X.; Yang, J.; Wang, L.; Zhou, Y.; Shen, Y.; Zhou, L.; Yu, Y.; Chen, S.; Zhang, X.; Wang, Z.: Arsenic trioxide induces multiple myeloma cell apoptosis via disruption of mitochondrial transmembrane potentials and activation of caspace-3. Chin. Med. J. Engl, 1999, 114, 19-24.
23. Halicka, H. D.; Smolewski, P.; Darzynkiewicz, Z.; Dai, W.; Traganos, E.: Arsenic trioxide arrests cells in mitosis leading to apoptosis. Cell Cycle, 2002, 1(3), 183-186.
24. Fenaux, P.; Chomienne C.; Degos, L.: Treatment of acute promyelocytic leukaemia. Clin Haematol. 2001, 14, 153-174.
25. Amadori, S.; Fenaux, P.; Ludwig, H.; O'dwyer, M.; Sanz, M.: Use of arsenic trioxide in haematological malignancies: insight into the clinical development of a novel agent. Curr Med Res Opin 2005, 21(3), 403-411.
26. Mayorga, J.; Richarson-Hardin, C.; Dicke, K. A.: Arsenic trioxide as effective therapy for relapsed acute promyelocytic leukemia. Clin J Oncol Nurs 2002, 6(6), 341-346.
27. Douer, D.; Tallman, M. S.: Arsenic trioxide: new clinical experience with an old medication in heamatologic malignancies. J Clin Oncol 2005, 23(10), 2396-2410.